Hospital Survey: Genentech’s Cancer Drug Distribution Change Raises Costs, Disrupts Care

by Admin | March 6, 2015 4:29 pm

March 6, 2015—Genentech’s decision last fall to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the specialty distribution channel has cost hospitals more than $300 million and disrupted patient care, a survey of more than 200 hospitals has found. Nearly two out of five hospitals (39 percent) surveyed said the change affects their risk of 340B program non-compliance. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2015/03/hospital-survey-genentechs-cancer-drug-distribution-change-raises-costs-disrupts-care/

---